Search the Newsreel

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Given Consensus Rating of "Moderate Buy" by Brokerages

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) has received a consensus "Moderate Buy" rating from twenty-four brokerages, with an average 12-month price target of $201.50. The company's stock opened at $156.49, has a market capitalization of $15.91 billion, and has seen significant insider selling totaling over $61 …

CDE- A Standout Silver Play that Delivered a Record Quarter

I still think it's too early to say the silver and gold price corrections are over. That said, I don't think we are likely to see new lows. Meanwhile, Coeur Mining Inc. (CDE) is a precious metals producer that's firing on all cylinders, suggests …

Euro India Fresh Foods standalone net profit rises 124.24% in the June 2026 quarter

EURO เตรียมจัด Earnings Call อัปเดตงบ Q2-แผนธุรกิจครึ่งปีหลัง 17 ส.ค.นี้

Coeur Mining (CDE) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Thursday, Aug. 6, 2026 at 11:00 a.m. ET CALL PARTICIPANTS President and Chief Executive Officer - Mitchell J. KrebsExecutive Vice President and Chief Financial Officer - Thomas S. WhelanExecutive Vice President and Chief Operating Officer - Michael RoutledgeSenior …

Stoneweg Europe Stapled Trust evaluates management internalisation, posts 1.4% rise in H1 DPS to 0.06642 euro

Stoneweg Europe Stapled Trust's H1 Distributable Income Flat at EUR37 Million

NeuroScientific Biopharmaceuticals (ASX:NSB) Share Performance in Focus as FDA Milestone Approaches

Can Eureka Group Holdings (ASX:EGH) Unlock Further Growth From Its Latest Mandurah Asset?

NeuroPace (NPCE) Stock Price Faces Flat Revenue And Lingering Losses

What's Going On With Euro Sun Mining Inc Stock Wednesday?

Capital World Investors (NASDAQ: KDP) discloses 8.8% Keurig Dr Pepper stake

Capital World Investors, a division of Capital Research and Management Company, has disclosed an 8.8% beneficial ownership stake in Keurig Dr Pepper Inc., totaling 120,099,461 shares. This filing, a Schedule 13G/A, indicates that the firm holds sole voting power over 117,777,759 shares and sole …

Alto Neuroscience Q2 EPS beats estimates; completes $100M financing

Alto Neuroscience (NYSE: ANRO) reported a Q2 2026 EPS of $(0.65), exceeding analyst estimates of $(0.73). The company also completed a $100 million financing round in July 2026, boosting its pro forma cash position to approximately $338 million, which is expected to fund operations …

ClearPoint Neuro (CLPT): MAK Capital group discloses 7.8% ownership in 13G/A

MAK Capital Fund LP, MAK Capital One L.L.C., and Michael A. Kaufman have filed a Schedule 13G/A, disclosing a collective beneficial ownership of 2,375,861 shares of ClearPoint Neuro, Inc. (CLPT) common stock. This represents 7.8% of the company's outstanding shares as of June 30, …

Alto Neuroscience (ANRO) boosts cash to $243.7M as R&D spend surges

Alto Neuroscience (ANRO) reported a net loss of $27.6 million for Q2 2026, widening from the previous year, primarily due to increased R&D expenses which surged to $22.1 million. Despite the loss, the company significantly strengthened its balance sheet, increasing cash and cash equivalents …

EURO-TREND-YAT-ORT, ETYAT Bilanço

EuroDry (NASDAQ:EDRY) Director Sells 500 Shares

EuroDry Director Aristeidis Pittas sold 500 shares of the company's stock for $18,900, reducing his holdings by 0.65%. This sale occurred shortly after EuroDry announced strong quarterly EPS of $2.44, significantly beating estimates, though revenue slightly missed expectations. The stock is trading near its …

EuroSports Global Limited Reports Earnings Results for the First Quarter Ended June 30, 2026

Minerva Neurosciences (NERV) elevates Anthony Aliquo to chief accounting officer role

Minerva Neurosciences (NERV) has promoted Anthony Aliquo to Chief Accounting Officer and principal accounting officer, effective August 10, 2026. This move includes an increase in his annual base salary to $296,696 and a performance bonus target of 35%. Frederick Ahlholm remains the Chief Financial …

NeuroPace Q2 Earnings Call Highlights

NeuroPace reported strong Q2 revenue growth driven by its RNS System for adult focal epilepsy, leading to a raised full-year revenue and adjusted EBITDA outlook. The company is also engaging with the FDA regarding expanding the RNS System's indication to idiopathic generalized epilepsy (IGE), …

Why Neurocrine Biosciences (NBIX) Stock Is Down Today

Neurocrine Biosciences (NBIX) stock is down 3.1% today, likely due to investor profit-taking and a reset of expectations following its late-July earnings release. While the company reported strong revenue growth and increased INGREZZA sales guidance, it also raised spending outlooks and highlighted the balance-sheet …

EuroDry (EDRY) corporate secretary sells 400 shares and holds 850 after trade

EuroDry Ltd.'s Corporate Secretary, Stefania Karmiri, reported the sale of 400 shares of common stock on August 11, 2026, at $38.50 per share. Following this transaction, she directly holds 850 shares of the company's common stock. The transaction was classified as an open market …

Euroholdings Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

EuroHoldings Q2 net profit rises 423% to $4.3 million

NERV Q2 2026 Earnings: Wider-than-Expected Loss Sends Shares Down 2.78% - Earnings Cycle Report

What's Going On With Neurocrine Biosciences Stock On Wednesday?

Neurocrine Biosciences stock experienced a dip after reports emerged of deaths and severe complications potentially linked to its drug Vykat XR, used for Prader-Willi syndrome. The FDA's adverse event data revealed seven deaths and over 100 serious events, primarily involving edema, respiratory, and cardiac …

Stoneweg Europe Stapled Trust refreshes board to bolster governance and succession

Euronet Worldwide (EEFT): Bank of Montreal group discloses 5.81% ownership stake

Bank of Montreal and its related entities have disclosed a passive ownership stake of 5.81% in Euronet Worldwide, Inc. (EEFT) common stock, totaling 2,214,718 shares. This information comes from a SCHEDULE 13G SEC filing, indicating that Bank of Montreal holds sole voting power over …

PRMB or CCEP: Which Is the Better Value Stock Right Now?

Investors with an interest in Beverages - Soft drinks stocks have likely encountered both Primo Brands (PRMB) and Coca-Cola European (CCEP). But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out. We …

NPCE Q2 Earnings Beat Estimates on RNS Growth, '26 Revenue View Up

NeuroPace (NPCE) reported strong second-quarter 2026 results, with earnings and revenues surpassing Zacks Consensus Estimates, driven by significant growth in its RNS System. The company also raised its full-year 2026 revenue guidance and improved its adjusted EBITDA loss outlook. NeuroPace highlighted advancements in AI-based …

Deaths reported after treatment with Neurocrine’s approved Prader-Willi drug

Reports have emerged of seven deaths and 100 serious adverse events potentially linked to Neurocrine Biosciences’ Prader-Willi syndrome drug, Vykat, prompting concerns among clinicians and patient advocacy groups. Concurrently, Aardvark Therapeutics terminated its Phase 3 trial for ARD-101 for the same condition due to …

Earnings To Watch: XBP Global Holdings Inc (XBP) Reports Q2 2026 Result

XBP Global Holdings Inc (NASDAQ:XBP) is slated to release its Q2 2026 earnings on August 13, 2026, with analysts forecasting a revenue of $197.70 million and an earnings per share of -$1.04. Despite upward revisions in revenue estimates for 2026 and 2027, earnings estimates …

Prader-Willi experts flag safety risks linked to Neurocrine's rare disease drug

Experts in Prader-Willi Syndrome have raised safety concerns regarding Neurocrine's drug Vykat XR, citing serious adverse events reported in patients. Post-marketing surveillance revealed reports of edema, respiratory and cardiac complications, and seven deaths linked to the drug as of July 31st, though no causal …

EuroHoldings Ltd Reports Results for the Quarter and Six-Month Period, Ended June 30, 2026

EuroHoldings declares $0.14 dividend payable around Sept. 16

Neurocrine Biosciences Announces Publication of KINECT-PRO™ Findings Demonstrating INGREZZA® (valbenazine) Capsules Improved Patient-Reported Quality of Life and Daily Functioning for People Living with Tardive Dyskinesia

Neurocrine Biosciences announced the publication of KINECT-PRO™ Phase 4 study results, showing that INGREZZA® (valbenazine) capsules significantly improved patient-reported quality of life and daily functioning, alongside clinician-rated tardive dyskinesia (TD) movement severity. These improvements were seen across various patient demographics, including those with mild …